MYRIAD GENETICS, INC. (MYGN) Operating Margin
- Operating margin · 12 months: Value -12.22%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -12.22% | Operating income / revenue. Period ending 2026-06-30. $-98.60M ÷ $806.60M × 100 ≈ -12.22% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -98.60M USD | Operating Income (Loss) |
| Revenue | 806.60M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 251.40M USD | Cost of Goods and Services Sold |
| Research and development | 105.80M USD | Research and Development Expense |
| Selling, general and administration | (m) | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-98.60M | $806.60M | $251.40M | $105.80M | (m) | -12.22% |
| 2026-03-31 | $-388.90M | $829.00M | $249.00M | $106.40M | (m) | -46.91% |
| 2025-12-31 | $-387.20M | $824.50M | $247.90M | $106.80M | (m) | -46.96% |
| 2025-09-30 | $-420.50M | $825.30M | $244.60M | $113.50M | (m) | -50.95% |
| 2025-06-30 | $-417.30M | $832.90M | $246.30M | $113.80M | (m) | -50.10% |
| 2025-03-31 | $-124.60M | $831.30M | $249.30M | $116.00M | (m) | -14.99% |
| 2024-12-31 | $-123.50M | $837.60M | $252.20M | $113.40M | (m) | -14.74% |
| 2024-09-30 | $-115.90M | $823.60M | (m) | $102.20M | $568.40M | -14.07% |
| 2024-06-30 | $-155.90M | $802.20M | (m) | $97.70M | $565.40M | -19.43% |
| 2024-03-31 | $-233.10M | $774.20M | (m) | $91.10M | $561.80M | -30.11% |
| 2023-12-31 | $-257.40M | $753.20M | (m) | $88.70M | $572.90M | -34.17% |
| 2023-09-30 | $-278.20M | $734.40M | (m) | $91.10M | $575.00M | -37.88% |
| 2023-06-30 | $-263.10M | $698.90M | (m) | $87.60M | $569.40M | -37.64% |
| 2023-03-31 | $-167.20M | $694.70M | (m) | $86.70M | $555.80M | -24.07% |
| 2022-12-31 | $-140.60M | $678.40M | (m) | $85.40M | $514.70M | -20.73% |
| 2022-09-30 | $-131.50M | $661.40M | (m) | $82.50M | $443.80M | -19.88% |
| 2022-06-30 | $-166.40M | $672.30M | (m) | $80.80M | $493.90M | -24.75% |
| 2022-03-31 | $-169.40M | $682.40M | (m) | $80.00M | $502.00M | -24.82% |
| 2021-12-31 | $-190.50M | $690.60M | (m) | $81.90M | $537.80M | -27.58% |
| 2021-09-30 | $-195.60M | $684.40M | (m) | $79.60M | $593.30M | -28.58% |
| 2021-06-30 | $-155.30M | $662.30M | (m) | $78.40M | $537.20M | -23.45% |
| 2021-03-31 | $-202.80M | $566.10M | (m) | $76.30M | $509.80M | -35.82% |
| 2020-12-31 | $-289.80M | $557.00M | (m) | $72.90M | $497.20M | -52.03% |
| 2020-09-30 | $-250.40M | $597.50M | (m) | $73.50M | $498.70M | -41.91% |
| 2020-06-30 | $-231.70M | $638.60M | (m) | $77.20M | $510.10M | -36.28% |
| 2020-03-31 | $-169.00M | $760.80M | (m) | $80.70M | $552.50M | -22.21% |
| 2019-12-31 | $-29.40M | $813.40M | (m) | $82.50M | $561.50M | -3.61% |
| 2019-09-30 | $-14.50M | $835.10M | (m) | $86.10M | $561.10M | -1.74% |
| 2019-06-30 | $7.60M | $851.10M | (m) | $85.90M | $555.50M | 0.89% |
| 2019-03-31 | $27.60M | $858.50M | (m) | $82.70M | $550.50M | 3.21% |
| 2018-12-31 | $35.70M | $825.00M | (m) | $79.70M | $517.60M | 4.33% |
| 2018-09-30 | $35.90M | $796.10M | (m) | $74.10M | $489.80M | 4.51% |
| 2018-06-30 | $118.70M | $772.60M | (m) | $70.80M | $467.10M | 15.36% |
| 2018-03-31 | $128.00M | $778.20M | (m) | $71.90M | $467.60M | 16.45% |
| 2017-12-31 | $118.70M | $781.70M | (m) | $71.00M | $474.70M | 15.18% |
| 2017-09-30 | $131.10M | $784.10M | (m) | $72.80M | $479.70M | 16.72% |
| 2017-06-30 | $49.40M | $771.40M | (m) | $74.40M | $476.40M | 6.40% |
| 2017-03-31 | $68.00M | $757.30M | (m) | $75.10M | $445.60M | 8.98% |
| 2016-12-31 | $97.70M | $750.90M | (m) | $74.70M | $414.00M | 13.01% |
| 2016-09-30 | $129.70M | $747.80M | (m) | $72.80M | $384.50M | 17.34% |
| 2016-06-30 | $166.80M | $753.80M | (m) | $70.60M | $359.10M | 22.13% |
| 2016-03-31 | $167.40M | $757.30M | (m) | $69.80M | $364.40M | 22.10% |
| 2015-12-31 | $160.40M | $746.70M | (m) | $69.30M | $365.20M | 21.48% |
| 2015-09-30 | $151.60M | $737.80M | (m) | $70.10M | $367.10M | 20.55% |
| 2015-06-30 | $134.20M | $723.10M | (m) | $75.50M | $366.00M | 18.56% |
| 2015-03-31 | $151.26M | $721.98M | (m) | $76.97M | $353.76M | 20.95% |
| 2014-12-31 | $170.80M | $724.92M | (m) | $73.70M | $350.11M | 23.56% |
| 2014-09-30 | $217.46M | $744.59M | (m) | $73.28M | $335.26M | 29.21% |
| 2014-06-30 | $274.44M | $778.22M | (m) | $67.48M | $327.10M | 35.27% |
| 2014-03-31 | $287.10M | $763.57M | (m) | $61.87M | $314.30M | 37.60% |
| 2013-12-31 | $289.74M | $737.12M | (m) | $62.09M | $291.27M | 39.31% |
| 2013-09-30 | $262.32M | $682.20M | (m) | $59.11M | $272.99M | 38.45% |
| 2013-06-30 | $228.00M | $613.16M | (m) | $53.71M | $251.84M | 37.18% |
| 2013-03-31 | $209.37M | $572.01M | (m) | $51.27M | $236.88M | 36.60% |
| 2012-12-31 | $197.55M | $545.32M | (m) | $49.40M | $226.97M | 36.23% |
| 2012-09-30 | $187.43M | $518.99M | (m) | $45.54M | $218.40M | 36.11% |
| 2012-06-30 | $180.32M | $496.00M | (m) | $42.65M | $208.38M | 36.35% |
| 2012-03-31 | $174.81M | $470.45M | (m) | $39.73M | $195.68M | 37.16% |
| 2011-12-31 | $170.54M | $443.05M | (m) | $34.65M | $183.73M | 38.49% |
| 2011-09-30 | $163.66M | $420.68M | (m) | $30.49M | $176.46M | 38.90% |
| 2011-06-30 | $157.78M | $402.08M | (m) | $27.75M | $169.84M | 39.24% |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | $135.07M | $362.65M | (m) | $21.87M | $161.41M | 37.25% |
| 2010-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | $126.46M | $326.53M | (m) | $17.91M | $138.88M | 38.73% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |